Phebra’s new plant
December 17, 2012
SYDNEY has a new manufacturing
plant, with Phebra confirming the
first stage of validation
manufacturing at its new plant at
Lane Cove West.
The first of a series of validation
batches of Phebra’s medicines
commenced last week ahead of the
plant’s TGA inspection and
licensing.
According to Phebra’s plans,
products being manufactured at
the plant will eventually cover the
company’s full range of critical
medicines, including emergency
injectables, antidotes and other
small volume injections.
“It is a credit to our General
Manager, Andre Vlok and his staff,
including external consultants, who
have planned and worked so
intensively for over 18 months to
bring this project to this stage - it’s
a wonderful Christmas present for
all concerned,” said Phebra CEO Dr
Mal Eutick.
“Phebra is excited that product
validation has commenced and that
once a TGA manufacturing licence
for the new facility has been
granted, we will be able to enhance
our capacity to manufacture critical
medicines for the local Australian
and New Zealand markets as well as
export markets.
“Furthermore, the extra rate of
production will expand Phebra’s
capacity and capability to conduct
all-important research programs,
now and into the future,” he
added.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Dec 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Dec 12
